EUR 2.95
(3.87%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 101.59 Million EUR | 44.05% |
2022 | 70.52 Million EUR | 112.96% |
2021 | 33.11 Million EUR | 19.53% |
2020 | 27.7 Million EUR | 77.98% |
2019 | 15.56 Million EUR | -14.54% |
2018 | 18.21 Million EUR | 75.86% |
2017 | 10.35 Million EUR | -21.15% |
2016 | 13.13 Million EUR | -26.22% |
2015 | 17.8 Million EUR | -17.67% |
2014 | 21.62 Million EUR | -23.05% |
2013 | 28.1 Million EUR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 Q4 | 101.59 Million EUR | 0.0% |
2023 FY | 101.59 Million EUR | 44.05% |
2023 Q2 | 78.48 Million EUR | 0.0% |
2022 FY | 70.52 Million EUR | 112.96% |
2022 Q2 | 38.66 Million EUR | 0.0% |
2022 Q4 | 70.52 Million EUR | 0.0% |
2021 FY | 33.11 Million EUR | 19.53% |
2021 Q1 | 29.96 Million EUR | 8.14% |
2021 Q2 | 28.69 Million EUR | -4.25% |
2021 Q4 | 33.11 Million EUR | 0.0% |
2020 FY | 27.7 Million EUR | 77.98% |
2020 Q2 | 26.99 Million EUR | 0.0% |
2020 Q4 | 27.7 Million EUR | 0.0% |
2019 Q4 | 15.56 Million EUR | 0.0% |
2019 FY | 15.56 Million EUR | -14.54% |
2019 Q2 | 19.42 Million EUR | 0.0% |
2018 Q4 | 18.21 Million EUR | 0.0% |
2018 FY | 18.21 Million EUR | 75.86% |
2018 Q2 | 17.4 Million EUR | 0.0% |
2017 FY | 10.35 Million EUR | -21.15% |
2017 Q4 | 10.35 Million EUR | 0.0% |
2017 Q2 | 10.4 Million EUR | 0.0% |
2016 Q4 | 13.13 Million EUR | 0.0% |
2016 FY | 13.13 Million EUR | -26.22% |
2016 Q2 | 15.48 Million EUR | 0.0% |
2015 FY | 17.8 Million EUR | -17.67% |
2015 Q4 | 17.8 Million EUR | 0.0% |
2014 FY | 21.62 Million EUR | -23.05% |
2013 FY | 28.1 Million EUR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
ABIONYX Pharma SA | 6.91 Million EUR | -1369.806% |
ABIVAX Société Anonyme | 131.05 Million EUR | 22.479% |
Adocia SA | 31.87 Million EUR | -218.773% |
Aelis Farma SA | 13.08 Million EUR | -676.705% |
Biophytis S.A. | 15.84 Million EUR | -541.006% |
Advicenne S.A. | 24.37 Million EUR | -316.758% |
genOway Société anonyme | 14.45 Million EUR | -602.603% |
IntegraGen SA | 5.97 Million EUR | -1598.937% |
Medesis Pharma S.A. | 6.42 Million EUR | -1480.923% |
Neovacs S.A. | 3.71 Million EUR | -2636.789% |
NFL Biosciences SA | 3.62 Million EUR | -2705.907% |
Plant Advanced Technologies SA | 6.78 Million EUR | -1397.902% |
Quantum Genomics Société Anonyme | 3.31 Million EUR | -2969.176% |
Sensorion SA | 13.22 Million EUR | -668.057% |
Theranexus Société Anonyme | 5.01 Million EUR | -1925.302% |
TME Pharma N.V. | 2.78 Million EUR | -3547.864% |
Valbiotis SA | 13.7 Million EUR | -641.122% |
TheraVet SA | 1.48 Million EUR | -6741.312% |
Valerio Therapeutics Société anonyme | 20.46 Million EUR | -396.35% |
DBV Technologies S.A. | 38.74 Million USD | -162.207% |
Genfit S.A. | 105.92 Million EUR | 4.086% |
GeNeuro SA | 20.13 Million EUR | -404.436% |
Innate Pharma S.A. | 132.29 Million EUR | 23.205% |
MaaT Pharma SA | 22.46 Million EUR | -352.228% |
MedinCell S.A. | 77.77 Million EUR | -30.633% |
Nanobiotix S.A. | 95.74 Million EUR | -6.113% |
OSE Immunotherapeutics SA | 59.07 Million EUR | -71.961% |
Poxel S.A. | 53.9 Million EUR | -88.481% |
GenSight Biologics S.A. | 34.72 Million EUR | -192.548% |
Transgene SA | 26.51 Million EUR | -283.124% |
Valneva SE | 341.14 Million EUR | 70.22% |